A large-scale analysis of the Surveillance, Epidemiology, and End Results (SEER) database indicates that omitting radiation therapy after breast-conserving surgery (BCS) does not negatively impact breast cancer-specific survival in older women with early-stage, estrogen receptor (ER)–positive breast cancer. While patients who received radiation showed a modest improvement in overall survival, researchers attribute this primarily to competing non-cancer health factors rather than breast cancer recurrence.
Shifting Trends in Post-Surgery Radiation
Clinical practice is moving away from universal radiation mandates for older patients. Data from a cohort of 50,845 women aged 70 and older, treated between 2000 and 2022, shows a clear shift in medical decision-making. In the early 2000s, roughly 25% of these patients bypassed radiation. By the 2018–2022 period, that omission rate climbed to more than 40%.
This trend aligns with findings from randomized trials suggesting that for specific low-risk groups, the side effects and logistical burden of daily radiation may outweigh the marginal clinical benefits. The study categorized patients into two groups: those receiving adjuvant beam radiation (32,540 patients) and those who did not (18,304 patients).
Did you know?
Most deaths among women in both the radiation and non-radiation groups were attributed to non-breast cancer causes, highlighting the importance of managing overall health in older patient populations.
Survival Outcomes and Clinical Considerations
The research found no statistically significant difference in breast cancer-specific survival (BCSS) between the two groups (adjusted hazard ratio [aHR], 0.95; 95% CI, 0.87-1.04). While the radiation group demonstrated a slightly better overall survival (aHR, 0.80; 95% CI, 0.75-0.86) over a median follow-up of 10 years, the divergence is linked to competing mortality risks rather than the efficacy of radiation in controlling the breast cancer itself.
Subgroup analysis provides more clarity for clinicians. Patients with tumors smaller than 1 cm and those over the age of 80 showed particularly comparable BCSS results regardless of whether they underwent radiation. These findings suggest that de-escalation is a viable, evidence-backed strategy for patients with smaller tumors.
Future Directions for Personalized Oncology
Frequently Asked Questions
Does skipping radiation increase the risk of dying from breast cancer in older women?
According to the SEER database study, there was no statistically significant difference in breast cancer-specific survival between women who received radiation and those who did not for this specific cohort.
Which patients are the best candidates for radiation omission?
The study highlights that women over age 80 and those with tumors measuring less than 1 cm had the most comparable outcomes, suggesting these groups are ideal candidates for discussing de-escalation.
Why did the radiation group show better overall survival if the cancer outcomes were the same?
The difference in overall survival is likely driven by competing mortality—non-cancer health issues—rather than a failure of treatment to control the breast cancer.
Are you or a loved one navigating a recent breast cancer diagnosis? Consult with a healthcare professional to see if current clinical guidelines for radiation de-escalation apply to your specific health profile. Explore our oncology resource library for more updates on evidence-based cancer care.
Related reading